Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium.


Journal Article (Review)

Mucormycosis is a difficult to diagnose rare disease with high morbidity and mortality. Diagnosis is often delayed, and disease tends to progress rapidly. Urgent surgical and medical intervention is lifesaving. Guidance on the complex multidisciplinary management has potential to improve prognosis, but approaches differ between health-care settings. From January, 2018, authors from 33 countries in all United Nations regions analysed the published evidence on mucormycosis management and provided consensus recommendations addressing differences between the regions of the world as part of the "One World One Guideline" initiative of the European Confederation of Medical Mycology (ECMM). Diagnostic management does not differ greatly between world regions. Upon suspicion of mucormycosis appropriate imaging is strongly recommended to document extent of disease and is followed by strongly recommended surgical intervention. First-line treatment with high-dose liposomal amphotericin B is strongly recommended, while intravenous isavuconazole and intravenous or delayed release tablet posaconazole are recommended with moderate strength. Both triazoles are strongly recommended salvage treatments. Amphotericin B deoxycholate is recommended against, because of substantial toxicity, but may be the only option in resource limited settings. Management of mucormycosis depends on recognising disease patterns and on early diagnosis. Limited availability of contemporary treatments burdens patients in low and middle income settings. Areas of uncertainty were identified and future research directions specified.

Full Text

Duke Authors

Cited Authors

  • Cornely, OA; Alastruey-Izquierdo, A; Arenz, D; Chen, SCA; Dannaoui, E; Hochhegger, B; Hoenigl, M; Jensen, HE; Lagrou, K; Lewis, RE; Mellinghoff, SC; Mer, M; Pana, ZD; Seidel, D; Sheppard, DC; Wahba, R; Akova, M; Alanio, A; Al-Hatmi, AMS; Arikan-Akdagli, S; Badali, H; Ben-Ami, R; Bonifaz, A; Bretagne, S; Castagnola, E; Chayakulkeeree, M; Colombo, AL; Corzo-León, DE; Drgona, L; Groll, AH; Guinea, J; Heussel, C-P; Ibrahim, AS; Kanj, SS; Klimko, N; Lackner, M; Lamoth, F; Lanternier, F; Lass-Floerl, C; Lee, D-G; Lehrnbecher, T; Lmimouni, BE; Mares, M; Maschmeyer, G; Meis, JF; Meletiadis, J; Morrissey, CO; Nucci, M; Oladele, R; Pagano, L; Pasqualotto, A; Patel, A; Racil, Z; Richardson, M; Roilides, E; Ruhnke, M; Seyedmousavi, S; Sidharthan, N; Singh, N; Sinko, J; Skiada, A; Slavin, M; Soman, R; Spellberg, B; Steinbach, W; Tan, BH; Ullmann, AJ; Vehreschild, JJ; Vehreschild, MJGT; Walsh, TJ; White, PL; Wiederhold, NP; Zaoutis, T; Chakrabarti, A; Mucormycosis ECMM MSG Global Guideline Writing Group,

Published Date

  • December 2019

Published In

Volume / Issue

  • 19 / 12

Start / End Page

  • e405 - e421

PubMed ID

  • 31699664

Pubmed Central ID

  • 31699664

Electronic International Standard Serial Number (EISSN)

  • 1474-4457

Digital Object Identifier (DOI)

  • 10.1016/S1473-3099(19)30312-3


  • eng

Conference Location

  • United States